Skip to main content

Advertisement

SpringerLink
Log in

Multiple myeloma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Multiple myeloma (MM) is an incurable plasma cell dyscrasia that remains fatal. Despite efforts over the past 3 to 4 decades, the median survival of patients with MM does not exceed 3 to 4 years. Although patients receiving combination chemotherapy have higher response rates compared with those receiving oral melphalan and prednisolone, they have no survival advantage. High-dose chemotherapy followed by autologous stem cell transplantation has documented benefit over conventional treatment and is currently the accepted mode of treatment for symptomatic MM. Allogeneic transplantation is associated with high complete remission rates, but at the cost of high therapy-related mortality. Maintenance treatment with interferon-a shows benefit, albeit in a small fraction of MM patients. The use of bisphosphonates in patients with MM has clearly demonstrated benefit and reduced morbidity associated with bone disease. All of these measures have improved remission rates and survival, but all patients with MM ultimately relapse and succumb to their disease. Novel therapeutic strategies are therefore required to improve outcome of MM patients. The responses noted to thalidomide in MM are encouraging. Immune-based strategies, including both adoptive immunotherapy and vaccinations, are currently being investigated in the preclinical and clinical setting, with the goal of enhancing autologous and allogeneic anti-MM immunity for therapeutic applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3–21. A recent review that covers an in-depth biology of MM

    PubMed  CAS  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics 1999. CA Cancer J Clin 1999, 49:12.

    Article  Google Scholar 

  3. Teoh G, Chen L, Urashima M, et al.: Adenovirus vector-based purging of multiple myeloma cells. Blood 1998, 92:4591–4601.

    PubMed  CAS  Google Scholar 

  4. Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55–65. The most updated results of tandem transplants for MM

    PubMed  CAS  Google Scholar 

  5. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756–763.

    PubMed  CAS  Google Scholar 

  6. Singhal S, Mehta J, Desikan R, et al.: Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571. The first demonstration of the efficacy of thalidomide in the treatment of heavily pretreated patients with MM. This is a novel approach in the therapy of MM

    Article  PubMed  CAS  Google Scholar 

  7. Raje N, Anderson KC: Thalidomide: a revival story. N Engl J Med 1999, 341:1606–1609. An editorial highlighting the use of thalidomide in the therapy of MM and its possible mechanisms of action

    Article  PubMed  CAS  Google Scholar 

  8. Schlossman SF, Alyea E, Orsini E, et al.: Immune based strategies to improve hematopoietic stem cell transplantation in multiple myeloma. In Autologous Marrow and Blood Transplantation. Edited by Dicke KA, Keating A. Charlottesville, VA: Carden, Jennings Publishing; 1999:207–221. A review detailing novel immune-based strategies currently under investigation for MM.

    Google Scholar 

  9. Preston DL, Kusumi S, Tomonaga M, et al.: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994, 137(suppl 2):S68-S97.

    Article  PubMed  CAS  Google Scholar 

  10. Stark AD, Chang HG, Fitzgerald EF, et al.: A retrospective cohort study of cancer incidence among New York State Farm Bureau members. Arch Environ Health 1990, 45:155–162.

    Article  PubMed  CAS  Google Scholar 

  11. Rettig MB, Ma HJ, Vescio RA, et al.: Kaposi’s sarcomaassociated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1851–1854.

    Article  PubMed  CAS  Google Scholar 

  12. Chauhan D, Bharti A, Raje N, et al.: Detection of Kaposi’s sarcoma herpesvirus-8 DNA sequences in multiple myeloma bone marrow stromal cells. Blood 1999, 93:1482–1486.

    PubMed  CAS  Google Scholar 

  13. Raje N, Kica G, Chauhan D, et al.: Kaposi’s sarcoma associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid 2000, in press.

  14. Myeloma Trialists’ Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832–3842. An overview of combination chemotherapy for MM.

    Google Scholar 

  15. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310:1353–1356.

    Article  PubMed  CAS  Google Scholar 

  16. Alexanian R, Yap BS, Bodey GP: Prednisone pulse therapy for refractory myeloma. Blood 1983, 62:572–577.

    PubMed  CAS  Google Scholar 

  17. Gore ME, Selby PJ, Viner C, et al.: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989, 8668:879–882.

    Article  Google Scholar 

  18. Raje N, Powles R, Kulkarni S, et al.: A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997, 97:153–160.

    Article  PubMed  CAS  Google Scholar 

  19. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 2:822–824.

    Article  PubMed  CAS  Google Scholar 

  20. Attal M, Harousseau JL, Stoppa AM, et al.: Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective, randomized trial. N Engl J Med 1996, 335:91–97. A landmark trial comparing prospectively the results of high-dose versus conventional therapy for the treatment of MM and demonstrating the superiority of high-dose therapy

    Article  PubMed  CAS  Google Scholar 

  21. Lenhoff S, Hjorth M, Holmberg E, et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a populationbased study. Blood 2000, 95:7–11.

    PubMed  CAS  Google Scholar 

  22. Chauhan D, Pandey P, Ogata A, et al.: Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997, 15:837–843.

    Article  PubMed  CAS  Google Scholar 

  23. Chauhan D, Hideshima T, Pandey P, et al.: RAFTK/ PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene 1999, 18:6733–6740.

    Article  PubMed  CAS  Google Scholar 

  24. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B: Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887–890.

    PubMed  CAS  Google Scholar 

  25. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986, 105:8–11.

    PubMed  CAS  Google Scholar 

  26. Salmon SE, Tesh D, Crowley J, et al.: Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1990, 8:1575–1584.

    PubMed  CAS  Google Scholar 

  27. Barlogie B, Jagannath S, Vesole DH, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789–793.

    PubMed  CAS  Google Scholar 

  28. Gahrton G, Tura S, Ljungman P, et al.: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312–1322. EBMT experience of allotransplants in the treatment of MM

    PubMed  CAS  Google Scholar 

  29. Bensinger WI, Buchner CD, Anasetti C, et al.: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 1996, 88:2787–2793. Seattle experience of allotransplants for MM

    PubMed  CAS  Google Scholar 

  30. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488–493. Randomized trial comparing the benefits of pamidronate therapy versus placebo for skeletal disease in patients with MM

    Article  PubMed  CAS  Google Scholar 

  31. Peest D: The role of alpha-interferon in multiple myeloma. Pathol Biol (Paris) 1999, 47:172–177.

    CAS  Google Scholar 

  32. D’Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082–4085.

    Article  PubMed  CAS  Google Scholar 

  33. Ribatti D, Vacca A, Nico B, et al.: Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999, 79:451–455.

    Article  PubMed  CAS  Google Scholar 

  34. Vacca A, Ribatti D, Presta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064–3073.

    PubMed  CAS  Google Scholar 

  35. Treon SP, Shima Y, Preffer I, et al.: Treatment of plasma cell dyscrasias by antibody mediated immunotherapy. Semin Oncol 1999, 5S4:97–106.

    Google Scholar 

  36. Powles R, Raje N, Milan S, et al.: Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997, 20:435–443.

    Article  PubMed  CAS  Google Scholar 

  37. Alegre A, Diaz-Mediavilla J, San-Miguel J, et al.: Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998, 21:133–140.

    Article  PubMed  CAS  Google Scholar 

  38. Mehta J, Tricot G, Jagannath S, et al.: Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998, 21:887–892.

    Article  PubMed  CAS  Google Scholar 

  39. Kulkarni S, Powles RL, Treleaven JG, et al.: Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant 1999, 23:675–680.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult Oncology, Dana-Farber Cancer Institute Department of Medicine, Harvard Medical School, 02115, Boston, MA, USA

    Noopur Raje MD & Kenneth C. Anderson MD

Authors
  1. Noopur Raje MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth C. Anderson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raje, N., Anderson, K.C. Multiple myeloma. Curr. Treat. Options in Oncol. 1, 73–82 (2000). https://doi.org/10.1007/s11864-000-0017-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0017-x

Keywords

Search

Navigation